Rules about research were mostly written in response to scandals. Knowing the cases explains why the rules look the way they do, and why some arguments are still open. PH 101 covers the Tuskegee study; this level looks at others.

Willowbrook and the Jewish Chronic Disease Hospital

From 1956 to 1971, researchers led by Saul Krugman at the Willowbrook State School on Staten Island, a crowded institution for children with intellectual disabilities, deliberately infected children with hepatitis to study the disease and test a protective treatment. They argued that most children there caught hepatitis anyway, that the study children got better care in a special unit, and that parents consented. Critics replied that the near certainty of infection was a symptom of terrible conditions the state should have fixed, and that at times the only open admission places were in the research unit, which made parental consent far from free. The work did advance knowledge of hepatitis, which is exactly why it remains a test case: good results do not settle whether the means were right.

In 1963 at the Jewish Chronic Disease Hospital in Brooklyn, doctors injected live cancer cells into elderly patients without telling them, to study immune responses. The researchers believed the cells would be rejected and thought mentioning cancer would frighten patients needlessly. The state medical licensing board disagreed and disciplined two of the physicians.

Henrietta Lacks

In 1951 doctors at Johns Hopkins took a sample of cervical cancer cells from Henrietta Lacks, a Black mother of five who died later that year. Her cells were taken and used without her knowledge, which was common practice at the time. They became HeLa, the first human cell line to grow indefinitely, and were used in work on the polio vaccine, cancer and much else. Her family learned of it decades later. The case raises questions current rules still struggle with: who controls tissue and genetic data once it leaves the body, and whether anyone besides companies should share in the profits. In 2013 the US National Institutes of Health agreed to give family members a voice in access to the HeLa genome.

Gelsinger and Havasupai

In 1999 Jesse Gelsinger, eighteen, died in a gene therapy trial at the University of Pennsylvania. Investigations found that the team had not promptly reported serious side effects in earlier subjects and that the lead researcher and the university held financial stakes in the company behind the therapy. The case put financial conflicts of interest at the center of research ethics.

In 1990, members of the Havasupai Tribe of Arizona gave blood to university researchers hoping to learn about diabetes. Their samples were later used for studies they had not agreed to, including research on schizophrenia, inbreeding and ancient migration, which contradicted the tribe's own account of its origins. Arizona State University settled with the tribe in 2010, paying $700,000 and returning the samples. Broad consent forms remain controversial for exactly this reason.

Equipoise and misconception

Randomized trials raise a deeper puzzle. A doctor owes each patient the best care, yet a trial assigns treatments by chance. The usual answer, defended by the philosopher Benjamin Freedman in 1987, is clinical equipoise: genuine uncertainty in the expert community about which treatment is better. If experts honestly disagree, no patient is knowingly given worse care. Once the evidence becomes clear, the trial should stop.

Participants often misunderstand this. Psychiatrist Paul Appelbaum and colleagues described the therapeutic misconception: participants believing a study is designed mainly to benefit them rather than to answer a question. Good consent processes work to correct it without crushing hope.

The global trials debate

In 1997 critics attacked trials in Africa, Asia and the Caribbean that tested a cheap, short course of the drug AZT to prevent mothers passing HIV to their babies. A longer course already worked in rich countries, but some trials compared the short course with a placebo. The debate turned on whether control groups abroad could receive less than the best proven treatment. Defenders said the long course was unaffordable there, the placebo group got what they would have gotten anyway, and only a placebo comparison would quickly show whether the cheap option worked. Critics said such a trial would never be allowed in the United States and that it used poor people as means. The debate shaped later revisions of the Declaration of Helsinki.

Worked example: a vaccine study abroad

A research group wants to test a new malaria vaccine in children in a rural district with no reliable clinic. Using the cases, a review board would ask: is there real equipoise about whether the vaccine helps? Will parents understand that this is research, not a free vaccination program, despite the therapeutic misconception? Do any researchers profit from the result, as at Penn? Who will control the blood samples, and could they be used for other studies, as with the Havasupai? Will every child in the trial, including the control group, get good malaria treatment if they fall ill, rather than the local standard of almost nothing? And if the vaccine works, will the district get it? A study that answers these questions well can be a real gift to the community. One that does not repeats old mistakes.